Pharmacist perspectives on emerging T cell-engaging bispecific therapies in cancer therapeutics
CONCLUSION: Bispecific therapies have continued to evolve the therapeutic landscape of cancer, primarily in hematological malignancies. Health-system pharmacists have the opportunity to play a key role in the operationalization and management of this new and emerging drug class.PMID:38394329 | DOI:10.1093/ajhp/zxae050
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Donald C Moore Naomi Digiantonio Carolyn J Oxencis Kate D Taucher Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Eye Cancers | Hematology | Lymphoma | Melanoma | Myeloma | Skin Cancer | Uveal Melanoma